Enterprise Value

-22.07M

Cash

160M

Avg Qtr Burn

-17.79M

Short % of Float

13.21%

Insider Ownership

0.83%

Institutional Own.

80.15%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details
Non-alcoholic steatohepatitis , Non-Alcoholic Fatty Liver Disease

Big Mover™

Susp. Mover™

Phase 2b

Data readout

HepTCell Details
Chronic hepatitis B

Big Mover™

Susp. Mover™

Phase 2

Data readout

Pemvidutide (ALT-801) (GLP-1R/GCGR) Details
Obesity

Big Mover™

Susp. Mover™

Phase 2

Data readout

Phase 1b

Update

Failed

Discontinued

Failed

Discontinued

NasoShield (Vaccine) Details
Anthrax, Bacterial infection

Failed

Discontinued

Failed

Discontinued